Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Genkyotex S.A.. (1/7/15). "Press Release: Genkyotex Raises CHF 20 Million ($21 Million)". Geneva & Archamps.

Organisations Organisation Genkyotex S.A. [old, until 2/17]
  Today Genkyotex Suisse S.A.
  Group Genkyotex (Group)
  Organisation 2 NeoMed Management (Jersey) Ltd.
  Group NeoMed (Group)
Products Product GKT831 (Genkyotex)
  Product 2 venture capital
Index term Index term Genkyotex–SEVERAL: investment, 201501 financing round Series D CHF20m=$21m led by new investor NeoMed Management
Persons Person Ney, Ursula M. (Genkyotex 201105– CEO before Antisoma COO before Charterhouse Therapeutics CEO)
  Person 2 Nessi, Claudio (NeoMed Management 201309)
     


Genkyotex, the leading developer of selective NOX inhibitors, today announced the completion of a CHF 20 million ($21 million) Series D financing. Proceeds will be used to complete a Phase 2 trial of GKT137831 in diabetic nephropathy, advance a second drug into Phase 1 trials, and broaden the Company’s pipeline of NOX inhibitors.

“This financing ensures we can continue independent development of our lead drug GKT137831 through Phase 2 results and prepare for the next phase of trials,” said Dr. Ursula Ney, CEO of Genkyotex. “We are also now well positioned to advance other promising candidates into our NOX inhibitor pipeline.”

The Company expects to report top-line data from the Phase 2a study of its NOX1&4 inhibitor GKT137831 in mid-2015. Genkyotex’s NOX1&4 inhibitors have shown potential in difficult-to-treat fibrotic and inflammatory disorders of the kidney, liver, lung and skin.

The financing was led by NeoMed Management, who along with co-leads VI Partners and BioMedInvest are new investors in the Company. Major existing investors Edmond de Rothschild Investment Partners, Eclosion2 and Vesalius Biocapital Partners were also significant participants. Dr. Claudio Nessi of NeoMed will join Genkyotex’s Board.

Dr. Nessi said “We have been very impressed with the progress made by Genkyotex, particularly in the clinical development of GKT137831. Genkyotex’s NOX inhibitors are a truly novel drug class with potential across many therapeutic areas, providing us with a compelling case for investment.”


About Genkyotex

Genkyotex is unlocking the potential of selective NOX enzyme inhibition to discover and develop a pipeline of drugs for hard to treat chronic diseases. For further information please visit www.genkyotex.com or contact:


For further information, contact:


Genkyotex*

Dr. Ursula Ney, CEO
Tel: +41228801025 / +447900898708
Email: ursula.ney@genkyotex.com

Dr. Daniel Elger, Chief Financial and Corporate Development Officer
Tel: + 447909915068
Email: daniel.elger@genkyotex.com


Halsin Partners

Mike Sinclair
Tel: +442073182955
Email: msinclair@halsin.com

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Genkyotex (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px




» top